Skip to content
naulon
Not checkedNot checked for notices yet.

Anticancer drugs for Parkinson's disease: Is it a ray of hope or only hype?

Deepa Dash, Vinay Goyal

Annals of Indian Academy of Neurology · 2019

doi:10.4103/aian.aian_177_18 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by the death of dopaminergic (DA) neurons in the substantia nigra. To develop therapeutic strategies to halt or slow the neurodegenerative process, it is imperative that we understand the pathogenesis of PD. With the current state of knowledge, multiple pathological pathways such as oxidative stress, inflammation due to microglial activation, apoptotic pathway activation via Abelson (c-Abl)tyrosine kinase enzyme, and DA toxins have been incriminated in causing DA neuronal death in PD. In the recent times, there is growing evidence of the role of c-Abl nonreceptor tyrosine kinase in the pathogenesis of PD. We give a short account of the potential of c-Abl inhibitors, the currently used anticancer drugs such as nilotinib in preventing the neurodegenerative process in PD.

Abstract licence: CC BY-NC-SA

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.